Clinical Trial Update: Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy [Phase 2]

View source ↗

Summary

A Phase 2 study completed evaluating the efficacy and safety of intravitreal aflibercept injections for subacute central serous chorioretinopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Serous Chorioretinopathy

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Asan Medical Center | Conditions: Central Serous Chorioretinopathy | Phase 2 | Status: COMPLETED